Peter O’Donnell, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses the phase II IMvigor 210 study, which led to the approval of PD-L1 inhibitor atezolizumab (Tecentriq) in May 2016 as a treatment for patients with locally advanced or metastatic urothelial carcinoma (mUC).
The study included over 300 patients who were all treated with prior platinum-based therapy in the metastatic setting. All patients received atezolizumab once every 3 weeks.
Atezolizumab had an overall response rate (ORR) of 15% in patients with locally advanced or mUC, regardless of PD-L1 expression. Among patients with PD-L1 expression ≥5%, ORR was 26%.
It is notable that the drug worked in patients that both did and did not express PD-L1, said O’Donnell.
The therapy was also quite tolerable. There was a 15% rate of grade 3 and 4 adverse events, an acceptable rate compared with other therapies used for metastatic disease, said O’Donnell.